Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome - A systematic review

被引:444
作者
Lindor, Noralane M.
Petersen, Gloria M.
Hadley, Donald W.
Kinney, Anita Y.
Miesfeldt, Susan
Lu, Karen H.
Lynch, Patrick
Burke, Wylie
Press, Nancy
机构
[1] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA
[2] Mayo Clin, Coll Med, Dept Med Genet, Rochester, MN USA
[3] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA
[4] NHGRI, Social & Behav Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[5] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA
[8] Maine Ctr Canc Med & Blood Disorders, Portland, ME USA
[9] Maine Med Ctr, Portland, ME 04102 USA
[10] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[11] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Houston, TX 77030 USA
[12] Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA
[13] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 12期
关键词
D O I
10.1001/jama.296.12.1507
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context About 2% of all colorectal cancer occurs in the context of the autosomal dominantly inherited Lynch syndrome, which is due to mutations in mismatch repair genes. Potential risk-reducing interventions are recommended for individuals known to have these mutations. Objectives To review cancer risks and data on screening efficacy in the context of Lynch syndrome (hereditary nonpolyposis colorectal cancer) and to provide recommendations for clinical management for affected families, based on available evidence and expert opinion. Data Sources and Study Selection A systematic literature search using PubMed and the Cochrane Database of Systematic Reviews, reference list review of retrieved articles, manual searches of relevant articles, and direct communication with other researchers in the field. Search terms included hereditary non-polyposis colon cancer, Lynch syndrome, microsatellite instability, mismatch repair genes, and terms related to the biology of Lynch syndrome. Only peer-reviewed, full-text, English-language articles concerning human subjects published between January 1, 1996, and February 2006 were included. The US Preventive Services Task Force's 2-tier system was adapted to describe the quality of evidence and to assign strength to the recommendations for each guideline. Evidence Synthesis The evidence supports colonoscopic surveillance for individuals with Lynch syndrome, although the optimal age at initiation and frequency of examinations is unresolved. Colonoscopy is recommended every 1 to 2 years starting at ages 20 to 25 years (age 30 years for those with MSH6 mutations), or 10 years younger than the youngest age of the person diagnosed in the family. While fully acknowledging absence of demonstrated efficacy, the following are also recommended annually: endometrial sampling and transvaginal ultrasound of the uterus and ovaries (ages 30-35 years); urinalysis with cytology (ages 25-35 years); history, examination, review of systems, education and genetic counseling regarding Lynch syndrome (age 21 years). Regular colonoscopy was favored for at-risk persons without colorectal neoplasia. For individuals who will undergo surgical resection of a colon cancer, subtotal colectomy is favored. Evidence supports the efficacy of prophylactic hysterectomy and oophorectomy. Conclusions The past 10 years have seen major advances in the understanding of Lynch syndrome. Current recommendations regarding cancer screening and prevention require careful consultation between clinicians, clinical cancer genetic services, and well-informed patients.
引用
收藏
页码:1507 / 1517
页数:11
相关论文
共 111 条
  • [1] Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
    Aaltonen, LA
    Salovaara, R
    Kristo, P
    Canzian, F
    Hemminki, A
    Peltomäki, P
    Chadwick, RB
    Kääriäinen, H
    Eskelinen, M
    Järvinen, H
    Mecklin, JP
    de la Chapelle, A
    Percesepe, A
    Ahtola, H
    Härkönen, N
    Julkunen, R
    Kangas, E
    Ojala, S
    Tulikoura, J
    ValKamo, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) : 1481 - 1487
  • [2] Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO
  • [3] 2-C
  • [4] Aarnio M, 1997, INT J CANCER, V74, P551, DOI 10.1002/(SICI)1097-0215(19971021)74:5<551::AID-IJC13>3.0.CO
  • [5] 2-9
  • [6] Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome
    Aarnio, M
    Mecklin, JP
    Aaltonen, LA
    NystromLahti, M
    Jarvinen, HJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) : 430 - 433
  • [7] *AG HEALTHC RES QU, US PREV HLTH SERV TA
  • [8] [Anonymous], 1983, JAMA, V249, P1600
  • [9] [Anonymous], NCCN PRACT GUID ONC
  • [10] hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients
    Apessos, A
    Mihalatos, M
    Danielidis, I
    Kallimanis, G
    Agnantis, NJ
    Triantafillidis, JK
    Fountzilas, G
    Kosmidis, PA
    Razis, E
    Georgoulias, VA
    Nasioulas, G
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (02) : 396 - 404